The FDA approved galcanezumab-gnlm (Emgality, Eli Lilly) to prevent migraine in adults.
Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene–related peptide and blocks its binding to the receptor preventing migraines. Galcanezumab-gnlm, which should be available soon, will be given as a once-monthly, self-administered subcutaneous injection.
The efficacy and safety of galcanezumab-gnlm were demonstrated in two phase 3 clinical
To read the full story, Log in or Sign up for a Free Account
We've added an exciting new feature to our website. Click on "Clinical" in the navbar to explore!
The following result is from the NPI Registry Public Search database. You can click on the NPI number to view detailed information and verify its accuracy. If your NPI is not found in this search, you can try searching again using the form below. If you have difficulty finding your NPI number please contact us at web@mcmahonmed.com
